Ignacio
Bernabeu Morón
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicacións en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (18)
2024
-
ERRATUM: Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-related cancer
-
Effectiveness of combined first-line medical treatment in acromegaly with prolactin cosecretion
European Journal of Endocrinology, Vol. 190, Núm. 6, pp. 458-466
-
Glucose metabolism outcomes after pituitary surgery in patients with acromegaly
Pituitary
-
Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs
Endocrine-Related Cancer, Vol. 31, Núm. 7
2023
-
Mortality in Acromegaly Diagnosed in Older Individuals in Spain Is Higher in Women Compared to the General Spanish Population
The Journal of clinical endocrinology and metabolism, Vol. 108, Núm. 9, pp. 2193-2202
2022
-
Factors associated with therapeutic response in acromegaly diagnosed in the elderly in Spain
Frontiers in Endocrinology, Vol. 13
2021
-
Craniopharyngioma in the Elderly: A Multicenter and Nationwide Study in Spain
Neuroendocrinology, Vol. 111, Núm. 10, pp. 925-936
2020
-
Diagnosis, treatment and follow-up of patients with acromegaly in a clinical practice setting in Spain: the ACROPRAXIS program Delphi survey
Pituitary, Vol. 23, Núm. 2, pp. 129-139
2018
-
Criteria for diagnosis and postoperative control of acromegaly, and screening and management of its comorbidities: Expert consensus
Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 5, pp. 297-305
2016
-
Long-term treatment with pegvisomant for acromegaly: A 10-year experience
Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550
-
Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY
Pituitary, Vol. 19, Núm. 2, pp. 127-137
-
Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study
Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408
2014
-
Escape and lipodystrophy in acromegaly during pegvisomant therapy, a retrospective multicentre Spanish study
Clinical Endocrinology, Vol. 81, Núm. 6, pp. 883-890
2013
-
Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues
European Journal of Endocrinology, Vol. 168, Núm. 1, pp. 9-13
-
Pegvisomant and cabergoline combination therapy in acromegaly
Pituitary, Vol. 16, Núm. 1, pp. 101-108
2009
-
Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radio therapy
European Journal of Endocrinology, Vol. 160, Núm. 4, pp. 535-542
2004
-
Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Español de Acromegalia, REA)
European Journal of Endocrinology, Vol. 151, Núm. 4, pp. 439-446
1991
-
Anterior Pituitary Function in Cushing's Syndrome: Studv of 36 Patients
Endocrinologia Japonica, Vol. 38, Núm. 5, pp. 559-563